Successful treatment of mixed (mainly cancer) pain by tramadol preparations by Kawahito, Shinji et al.
INTRODUCTION
Tramadol is a weak opioid analgesic used clinically at ‘step 2’ of
the World Health Organization (WHO) three-step cancer pain relief
ladder. It is available in Japan for non-cancer-related chronic pain
including neuropathic pain. Tramadol is a racemate, and its enanti-
omers and their active metabolites can act as a weak agonist for µ-
opioid receptors and a weak reuptake inhibitor for noradrenaline
and serotonin (14).
Various tramadol preparations have been developed, and they
have become an effective therapeutic approach to chronic pain
including cancer pain. In this case report, we describe the useful-
ness of some tramadol preparations for mixed (mainly cancer)
pain.
CASE REPORT
The patient was a 70-year-old Japanese woman. She had a
history of hypertension, diabetes mellitus, multiple sclerosis and
lumbar spinal canal stenosis. Following the diagnosis of a parotid
gland tumor (adenocarcinoma), the patient underwent wide exci-
sion and reconstruction (facial nerve ablation, nerve transposition) at
another university hospital. At 1 month after this surgery, she was
brought to our hospital’s pain medicine department because her
postoperative and cancer-related pain were poorly controlled. She
was taking five tramadol (37.5 mg)/acetaminophen (325 mg)
combination tablets (Tramcet Combination Tablets) per day, but
in addition to the continuous pain in her face and lower limbs, she
was troubled by a trigeminal neuralgia- like prominence ache that
lasted for approx. 10 minutes several times a day.
We switched the patient’s pain medication to a tramadol capsule
(Tramal Capsule) because although her pain medication had been
increased to eight of the above-named combination tablet per day,
her pain was not well -controlled. The initial dosage was a total of
300 mg/day, and we added an adjuvant agent, i.e., an anti - infla-
mmatory analgesic : cerecoxib (Cerecox).
At 11 months post-surgery, we switched the patient’s pain
medication to a daily tramadol orally disintegrating tablet (Tramal
OD Tablet) to improve medication adherence of the drug. At 14
months post-surgery, she was also given a tramadol sustained-
release preparation (Onetram Tablet) to use daily in addition to
the Tramal OD Tablet, and she was then able to sleep well at night.
The combination of the orally disintegrating tablet and the sus-
tained-release preparation provides a total of 400 mg tramadol per
day, and she then achieved sufficient pain relief.
One month after the start of the new medication regimen, the
patient underwent lumbar spinal surgery. Her lumbago and the
lower extremity pain were then relieved, and the dose of tramadol
was decreased to 300 mg/day. She was prescribed a prophylactic
antiemetic (prochlorperazine maleate [Novamin]) and a laxative
(sennoside [Pursennid]) together, and no side effects were ob-
served.
DISCUSSION
Various opioid preparations are now authorized in Japan for the
treatment of chronic pain. As we have described in this case report,
various tramadol preparations can be very effective against mixed
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pain, including pain due mainly to cancer. The WHO’s three-step
analgesic ladderwhich was originally proposed for cancer pain
reliefis now widely used for all types of pain, including chronic
pain from musculoskeletal disease. Tramadol, an analgesic that
has monoaminergic activity and weak opioid receptor affinity, has
proved suitable for use at Step 2 of the WHO ladder (14). As a
centrally acting analgesic structurally related to codeine and mor-
phine, tramadol consists of two enantiomers, which contribute to
the analgesic activity via different mechanisms (Figure). It has
been shown that (+) - tramadol and the metabolite (+) -O-desmethyl -
tramadol (M1) act against the µ-opioid receptor. The enantiomer
(+)- tramadol inhibits serotonin reuptake, whereas (-) - tramadol
inhibits norepinephrine reuptake, enhancing tramadol’s inhibitory
effect on pain transmission in the spinal cord.
The complementary and synergistic actions of the two enanti-
omers improve the analgesic efficacy and tolerability profile of the
racemate. Tramadol is metabolized mainly by O- and N-demet-
hylation and by conjugation reactions forming glucuronides and
sulfates. Tramadol and its metabolites are excreted mainly via the
kidneys. The mean elimination half - life is approx. 6hr.
Several tramadol preparations were developed recently, and
tramadol has become an effective therapeutic approach to chronic
(including cancer-related) pain (4). In Japan, tramadol is available
as a capsule, an orally disintegrating tablet, an injection, and a com-
pounded agent with acetaminophen. An oral once-daily extended-
release dosage form has also been reported to be effective for severe
pain (5). The tramadol sustained-release preparation Onetram is a
tablet with a dual -bicornate nature, providing both an immediate
effect and controlled release characteristics. With Onetram we
can obtain an effect that is equivalent to that of Tramal (which is
administered 4/day) by a 1/day administration.
Tramadol has a low incidence of adverse effects, particularly
regarding respiratory depression, constipation and abuse poten-
tial, and it has never been a scheduled drug. The abuse of tramadol
has remained very low despite new branded and generic formula-
tions (6). The most common side effects of tramadol are somno-
lence, constipation, dizziness, nausea, and orthostatic hypoten-
sion, which occur more frequently with rapid dosage escalation
(7). Tramadol can cause or exacerbate cognitive impairment and
gait disturbances in elderly patients. It can also precipitate sei-
zures in individuals with a history of seizures or in those receiving
medications that reduce seizure threshold. Concurrent use of
other serotonergic medications may increase the risk of serotonin
syndrome, and combination therapy with these medications must
be undertaken cautiously (8). We can control the side effects of
tramadol such as nausea, constipation, sleepiness, and withdrawal
signs. In our patient, no signs of dependence were observed over
the entire course of treatment.
CONCLUSION
Tramadol offers an important alternative to other opioids, because
the complementary and synergistic actions of the two enantiomers
(µ-opioid and serotonin reuptake inhibitor of norepinephrine and
serotonin) enhance its analgesic effects and improve its tolerability
profile. Because tramadol is not a scheduled medical narcotic
drug, it is widely available in outpatient pain medicine departments.
Here, tramadol was extremely useful for our patient’s mixed
(mainly cancer) pain. We expect tramadol to provide a useful
contribution to palliative medicine in the future.
We presented aspects of this paper at the 21st Congress of the
Japanese Society for Palliative Medicine (2016, Kyoto, Japan).
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